JMP Group Inc. (NYSE:JMP), an investment banking and alternative asset management firm, announced today that Oren G. Livnat has joined JMP Securities as a director and senior research analyst following the specialty pharmaceuticals industry. Mr. Livnat is based in the firm’s New York office.
“Oren is well regarded by institutional investors and will be an important contributor to our healthcare franchise,” said Thomas R. Wright, director of equities at JMP Securities. “His coverage of specialty pharmaceuticals will dovetail with JMP’s biotechnology, medical devices, and life science tools and diagnostics research and will bring the total number of senior analysts devoted to those sectors at JMP to six. These areas are highly complex, and JMP works constantly to provide its brokerage clients with much needed perspective and actionable insights that can lead to winning investments in the space.”
Prior to joining JMP Securities, Mr. Livnat spent four years in equity research at Jefferies & Company, where he covered development-stage and commercial-stage brand and generic specialty pharmaceutical companies, with a specific focus on CNS, pain and specialty generics. Mr. Livnat previously worked in equity research following specialty pharmaceuticals at Natixis Bleichroeder. Mr. Livnat received a BA in economics from Wesleyan University and is a CFA charterholder.
About JMP Group
JMP Group Inc. is an investment banking and asset management firm that provides investment banking, sales and trading, and equity research services to corporate and institutional clients and alternative asset management products to institutional and high-net-worth investors. JMP Group operates through three subsidiaries: JMP Securities, Harvest Capital Strategies and JMP Credit Advisors. For more information, visit www.jmpg.com.
Contacts:
JMP Group Inc.
Andrew
Palmer, 415-835-8978
apalmer@jmpg.com
or
Media
Relations Contact
Dukas Public Relations
Seth Linden,
212-704-7385
seth@dukaspr.com
Zach
Leibowitz, 212-704-7385
zach@dukaspr.com